Joint Research and Business Relationships with Hiroshima University
First written in FY2016. 5 of 9 entries say "Softened", first in FY2017. Latest entry: FY2025.
PhoenixBio moved to the "Worse" side of this theme in 2017, 8 years before the typical company in this theme (2025).
The whole theme swung hardest in 2020: 2 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Reframed".
- FY2025ReframedAnnual report
「In addition to conducting research in-house, the Group conducts joint research with Hiroshima University, a national university corporation. The Group intends to maintain a good relationship with the university and continue joint research, but if renewing the agreement becomes difficult, this could adversely affect the Group's research and development activities.」
The disclosure on the relationship with Hiroshima University has shifted from a focus on sales concentration to a risk disclosure focused on renewal of the joint research agreement and its impact on research and development activities. - FY2023SoftenedAnnual report
「Although the university's share of sales has been declining as the Group's sales have expanded, it remains a major customer.」
Hiroshima University remains a major customer, while its share of sales has been trending downward as sales have expanded. - FY2022SoftenedAnnual report
「The university is also a major customer, accounting for 3.0% of the Group's net sales in the fiscal year ended March 2022.」
Hiroshima University's share of net sales declined from 4.6% in the previous full-year disclosure to 3.0%, reducing sales concentration. The risk associated with the joint research and business relationship continues. - FY2021WorsenedAnnual report
「The university is also a major customer, accounting for 4.6% of the Group's net sales in the fiscal year ended March 2021.」
Hiroshima University's share of net sales rose from 3.6% in the previous fiscal year to 4.6%, increasing sales concentration in the university. - FY2020SoftenedAnnual report
「The university is also a major customer, accounting for 3.6% of the Group's net sales in the fiscal year ended March 2020.」
Hiroshima University's share of net sales declined from 6.7% in the previous fiscal year to 3.6%, reducing sales concentration in the university. The risk associated with the joint research and business relationship continues. - FY2019SoftenedAnnual report
「The university is also a major customer, accounting for 6.7% of the Group's net sales in the fiscal year ended March 2019.」
Hiroshima University's share of net sales declined from 11.4% in the previous fiscal year to 6.7%, reducing sales concentration in the university. The risk inherent in the joint research and business relationship continues. - FY2018WorsenedAnnual report
「The university is also a major customer, accounting for 11.4% of the Group's net sales in the fiscal year ended March 2018.」
Hiroshima University's share of net sales rose from 8.9% in the previous fiscal year to 11.4%, increasing sales concentration in the university. - FY2017SoftenedAnnual report
「The university is also a major customer, accounting for 8.9% of the Group's net sales in the fiscal year ended March 2017.」
Hiroshima University's share of net sales declined from 9.8% in the previous fiscal year to 8.9%, but the risk of dependence on the joint research and business relationship continues. - FY2016First statedAnnual report
「The university is also a major customer, accounting for 9.8% of the Group's net sales in the fiscal year ended March 2016. The Group intends to maintain a good relationship with the university and continue joint research, but if renewing the agreement becomes difficult, or if business dealings become difficult due to termination or for any other reason, this could adversely affect the Group's business.」
The continuation of joint research and business dealings with Hiroshima University, a major customer accounting for 9.8% of net sales, is treated as an important relationship.